Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
03 mai 2024 11h23 HE
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
26 avr. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
26 avr. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
24 avr. 2024 10h00 HE
|
CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
19 mars 2024 08h00 HE
|
Ludwig Enterprises, Inc.
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence...
Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers
06 mars 2024 08h00 HE
|
Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent
Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Forecasts to 2034
25 janv. 2024 09h04 HE
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Non-muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The...
Oncology Nutrition Market Experiences Growth with Rise in Personalized and Immuno-nutrition Trends
22 janv. 2024 21h28 HE
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The recent comprehensive analysis within...
Non-Muscle Invasive Bladder Cancer Market Analysis, Competitive Landscape, Growth Factors, Revenue & Forecasts, 2023-2030 – Published Study by RationalStat
27 nov. 2023 06h45 HE
|
Rationalstat LLC
Wilmington, Delaware, Nov. 27, 2023 (GLOBE NEWSWIRE) -- According to RationalStat’s most recent industry analysis, the Global Non-Muscle Invasive Bladder Cancer Market value is estimated at US$ 2.5...
Intelligent Scopes Corp, Subsidiary of Claritas HealthTech, to Lead Global Delivery of CystoSmart™, an AI-Assisted Diagnostic Software for Bladder Cancer Detection in Endoscopic Images
12 nov. 2023 19h13 HE
|
Claritas HealthTech Ltd
Intelligent Scopes Corp, Subsidiary of Claritas HealthTech, to Lead Global Delivery of CystoSmart™, an AI-Assisted Diagnostic Software for Bladder Cancer